# Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML

> **NCT05404516** · PHASE2 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 88 (estimated)

## Conditions studied

- Core Binding Factor Acute Myeloid Leukemia

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT05404516
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2022-08-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2022-06-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05404516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05404516, "Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05404516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*